APEIRON Biologics AG, based in Vienna, Austria, is a biotech company with a focus on biological and immunological approaches to treat cancer. The company was founded by Professor Josef Penninger and became operational in 2006. Apeiron currently employs about 35 people and is led by a management team with strong background in drug development, especially in immuno-oncology.


Apeiron's lead project APN311, an antibody-based therapy to treat patients suffering from neuroblastoma (a rare childhood cancer) has completed clinical development and its first application for marketing authorization is under review.
See projects for the present status of Apeiron's portfolio.

 

  • 1598 hits11 May 2017

    Marketing Approval for Children’s Cancer Immunotherapy in the EU: Outstanding Success for privately financed Austrian Biotech Company Apeiron

    On May 8, 2017, The European Commission has granted marketing authorization for “Dinutuximab beta Apeiron”, an antibody-based immunotherapy the rare pediatric cancer neuroblastoma. The notification of approval can be found on the homepage of the European Comission http://ec.europa.eu/health/documents/community-register/html/newproc.htm#h. Thanks to the Vienna-based Biotech company Apeiron Biologics AG (“Apeiron”) patients in Europe are now offered an additional treatment option with a promising therapy – a result of a collaborative effort of management and employees, academic institutions, Austrian private investors, business angels as well as public and private research initiatives.

     Presseaussendung

     Press Release